Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multidrug resistance and malignancy in human osteosarcoma

K Scotlandi1, M Serra, G Nicoletti

  • 1Dipartimento di Oncologia, Istituti Ortopedici Rizzoli, Bologna, Italy.

Cancer Research
|May 15, 1996
PubMed
Summary

Multidrug-resistant (MDR) osteosarcoma cells expressing P-glycoprotein show reduced metastasis. This suggests MDR phenotype

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A retrospective analysis of phase I and phase I/II investigator-initiated clinical trials conducted by the Swiss Group for Clinical Cancer Research (SAKK).

ESMO open·2025
Same author

Reliability of toxicokinetic modelling for PFAS exposure assessment in contaminated water in northern Italy.

Heliyon·2024
Same author

A systematic review of contemporary phase I trials in patients with lymphoma.

Critical reviews in oncology/hematology·2022
Same author

Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2021
Same author

Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.

Leukemia·2016

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Osteosarcoma treatment failure is linked to chemotherapy resistance and metastasis.
  • P-glycoprotein (encoded by MDR1 gene) overexpression predicts poor outcomes in osteosarcoma patients.
  • The relationship between P-glycoprotein expression and osteosarcoma aggressiveness requires further investigation.

Purpose of the Study:

  • To investigate the association between P-glycoprotein expression and the local aggressiveness and metastatic potential of multidrug-resistant (MDR) human osteosarcoma cells.
  • To correlate in vitro findings with clinical data from osteosarcoma patients.

Main Methods:

  • In vitro studies using multidrug-resistant (MDR) and parental sensitive osteosarcoma cell lines to assess migratory, invasive, and adhesion abilities.

Related Experiment Videos

  • In vivo studies in athymic mice to evaluate tumorigenicity and metastatic potential.
  • Clinical data analysis correlating P-glycoprotein expression in primary tumors with metastasis timing and disease stage at diagnosis.

    • Main Results:

    • MDR osteosarcoma cells overexpressing P-glycoprotein exhibited decreased tumorigenicity and metastatic ability in mice.
    • In vitro, these cells showed reduced migration, invasion, and homotypic adhesion.
    • Clinical data revealed a longer time to lung metastasis in patients with P-glycoprotein overexpression and a higher incidence of overexpression in localized disease.
    • P-glycoprotein overexpression was more frequent in patients with localized disease than in those with existing metastases.

    Conclusions:

    • P-glycoprotein overexpression in osteosarcoma is associated with a less aggressive phenotype in vitro and in vivo.
    • Clinical findings support that the MDR phenotype in osteosarcoma is not linked to increased metastatic ability.
    • The adverse clinical outcome associated with MDR osteosarcoma is likely due to drug resistance rather than enhanced metastatic potential.